Literature DB >> 22177949

Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition.

Antonia Caroli1, Silvia Simeoni, Rosalba Lepore, Anna Tramontano, Allegra Via.   

Abstract

Schistosoma mansoni and Plasmodium falciparum are pathogen parasites that spend part of their lives in the blood stream of the human host and are therefore heavily exposed to fluxes of toxic reactive oxygen species (ROS). SmTGR, an essential enzyme of the S. mansoni ROS detoxification machinery, is known to be inhibited by Auranofin although the inhibition mechanism has not been completely clarified. Auranofin also kills P. falciparum, even if its molecular targets are unknown. Here, we used computational and docking techniques to investigate the molecular mechanism of interaction between SmTGR and Auranofin. Furthermore, we took advantage of the homology relationship and of docking studies to assess if PfTR, the SmTGR malaria parasite homologue, can be a putative target for Auranofin. Our findings support a recently hypothesized molecular mechanism of inhibition for SmTGR and suggest that PfTR is indeed a possible and attractive drug target in P. falciparum.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177949     DOI: 10.1016/j.bbrc.2011.12.009

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.

Authors:  Derek Parsonage; Fang Sheng; Ken Hirata; Anjan Debnath; James H McKerrow; Sharon L Reed; Ruben Abagyan; Leslie B Poole; Larissa M Podust
Journal:  J Struct Biol       Date:  2016-02-12       Impact factor: 2.867

Review 2.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

Review 3.  Gold-based therapy: From past to present.

Authors:  Alice Balfourier; Jelena Kolosnjaj-Tabi; Nathalie Luciani; Florent Carn; Florence Gazeau
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-08       Impact factor: 11.205

4.  Activity of Auranofin against Multiple Genotypes of Naegleria fowleri and Its Synergistic Effect with Amphotericin B In Vitro.

Authors:  Jose Ignacio Escrig; Hye Jee Hahn; Anjan Debnath
Journal:  ACS Chem Neurosci       Date:  2020-05-26       Impact factor: 4.418

5.  In vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites.

Authors:  Fabienne Barna; Karim Debache; Carsten A Vock; Tatiana Küster; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

6.  Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads.

Authors:  Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-03-11       Impact factor: 5.854

7.  Auranofin: repurposing an old drug for a golden new age.

Authors:  Christine Roder; Melanie J Thomson
Journal:  Drugs R D       Date:  2015-03

8.  Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.

Authors:  Christina A Bulman; Chelsea M Bidlow; Sara Lustigman; Fidelis Cho-Ngwa; David Williams; Alberto A Rascón; Nancy Tricoche; Moses Samje; Aaron Bell; Brian Suzuki; K C Lim; Nonglak Supakorndej; Prasit Supakorndej; Alan R Wolfe; Giselle M Knudsen; Steven Chen; Chris Wilson; Kean-Hooi Ang; Michelle Arkin; Jiri Gut; Chris Franklin; Chris Marcellino; James H McKerrow; Anjan Debnath; Judy A Sakanari
Journal:  PLoS Negl Trop Dis       Date:  2015-02-20

9.  Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway.

Authors:  Shankar Thangamani; Matthew Maland; Haroon Mohammad; Pete E Pascuzzi; Larisa Avramova; Carla M Koehler; Tony R Hazbun; Mohamed N Seleem
Journal:  Front Cell Infect Microbiol       Date:  2017-01-18       Impact factor: 5.293

10.  Characterization of Entamoeba histolytica adenosine 5'-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis.

Authors:  Fumika Mi-Ichi; Takeshi Ishikawa; Vo Kha Tam; Sharmina Deloer; Shinjiro Hamano; Tsuyoshi Hamada; Hiroki Yoshida
Journal:  PLoS Negl Trop Dis       Date:  2019-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.